P002 Real-world experiences of biologic tapering

Abstract Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on biologic therapy who remain in clinical remission. NICE guidance suggests “cautiously reducing drug doses or stopping drugs in those who have mainta...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 60; no. Supplement_1
Main Authors Rutter-locher, Zoe, Man, Yik Long, Marsh, Lydia, Mercer, Scott, Menon, Bina, Cope, Andrew
Format Journal Article
LanguageEnglish
Published Oxford University Press 25.04.2021
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on biologic therapy who remain in clinical remission. NICE guidance suggests “cautiously reducing drug doses or stopping drugs in those who have maintained the treatment target”. Despite this guidance, little is known about current clinical practice of biologic tapering in UK rheumatology centres. We aimed to illustrate current practice and success rates in biologic tapering in a real-world setting in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS). Methods  We identified patients who were potentially suitable for biologic tapering 1 week prior to their follow up appointment using the following criteria - any anti-TNFα biologic ≥ 1 year, RA patients (DAS28 CRP<3.2, CRP normal), PSA patients (no swollen joints, CRP normal, no extra-articular manifestations), AS patients (BASDAI<4, CRP normal). We then analysed how many patients were successfully tapered at one year. Tapering schedule was decided by the supervising rheumatologist. Results  From December 2018 to February 2019, 66 patients were identified as being suitable for biologic tapering. 3 patients did not attend and were excluded from further analysis. Tapered group: 20 (32%) patients were tapered. Based on the retrospective review of clinic letters, the “tapering schedule” was inconsistent and the information provided to patients if they flared was also inconsistent - 9 (45%) patients were advised to return to their normal dose and only 1 (5%) patient was advised to contact the helpline. After 12 months of follow up, 11 (55%) patients remained on the tapered dose, 7 (35%) patients returned to their prior dose and 2 (10%) patients were lost to follow up. Non-tapered group: 43 (68%) patients were not tapered. The reasons for not tapering were divided into 6 broad categories: active disease (n = 15, 35%), patient choice (n = 5, 12%), DMARD was tapered instead (n = 5, 12%), discuss at next visit (n = 3, 7%), reason not mentioned (n = 12, 28%), other (n = 3, 7%) Conclusion  This Quality Improvement Project has highlighted the inconsistencies in biologic tapering in a UK real-world setting. In response to this inconsistency, we have developed a departmental guideline which provides stringent criteria to identify patients at lowest risk of flaring and standardises a tapering schedule and clinical pathway. We also created a patient information leaflet that could be distributed. Only half of the patients remained on the tapered dose after 1 year, suggesting a significant proportion of patients flare following dose reduction. However, our findings may be limited by small sample size. National guidance and a thorough audit based on this guidance is welcomed. Disclosure  Z. Rutter-locher: None. Y. Long Man: None. L. Marsh: None. S. Mercer: None. B. Menon: None. A. Cope: None.
AbstractList Abstract Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on biologic therapy who remain in clinical remission. NICE guidance suggests “cautiously reducing drug doses or stopping drugs in those who have maintained the treatment target”. Despite this guidance, little is known about current clinical practice of biologic tapering in UK rheumatology centres. We aimed to illustrate current practice and success rates in biologic tapering in a real-world setting in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS). Methods  We identified patients who were potentially suitable for biologic tapering 1 week prior to their follow up appointment using the following criteria - any anti-TNFα biologic ≥ 1 year, RA patients (DAS28 CRP<3.2, CRP normal), PSA patients (no swollen joints, CRP normal, no extra-articular manifestations), AS patients (BASDAI<4, CRP normal). We then analysed how many patients were successfully tapered at one year. Tapering schedule was decided by the supervising rheumatologist. Results  From December 2018 to February 2019, 66 patients were identified as being suitable for biologic tapering. 3 patients did not attend and were excluded from further analysis. Tapered group: 20 (32%) patients were tapered. Based on the retrospective review of clinic letters, the “tapering schedule” was inconsistent and the information provided to patients if they flared was also inconsistent - 9 (45%) patients were advised to return to their normal dose and only 1 (5%) patient was advised to contact the helpline. After 12 months of follow up, 11 (55%) patients remained on the tapered dose, 7 (35%) patients returned to their prior dose and 2 (10%) patients were lost to follow up. Non-tapered group: 43 (68%) patients were not tapered. The reasons for not tapering were divided into 6 broad categories: active disease (n = 15, 35%), patient choice (n = 5, 12%), DMARD was tapered instead (n = 5, 12%), discuss at next visit (n = 3, 7%), reason not mentioned (n = 12, 28%), other (n = 3, 7%) Conclusion  This Quality Improvement Project has highlighted the inconsistencies in biologic tapering in a UK real-world setting. In response to this inconsistency, we have developed a departmental guideline which provides stringent criteria to identify patients at lowest risk of flaring and standardises a tapering schedule and clinical pathway. We also created a patient information leaflet that could be distributed. Only half of the patients remained on the tapered dose after 1 year, suggesting a significant proportion of patients flare following dose reduction. However, our findings may be limited by small sample size. National guidance and a thorough audit based on this guidance is welcomed. Disclosure  Z. Rutter-locher: None. Y. Long Man: None. L. Marsh: None. S. Mercer: None. B. Menon: None. A. Cope: None.
Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on biologic therapy who remain in clinical remission. NICE guidance suggests “cautiously reducing drug doses or stopping drugs in those who have maintained the treatment target”. Despite this guidance, little is known about current clinical practice of biologic tapering in UK rheumatology centres. We aimed to illustrate current practice and success rates in biologic tapering in a real-world setting in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA) and ankylosing spondylitis (AS). Methods  We identified patients who were potentially suitable for biologic tapering 1 week prior to their follow up appointment using the following criteria - any anti-TNFα biologic ≥ 1 year, RA patients (DAS28 CRP<3.2, CRP normal), PSA patients (no swollen joints, CRP normal, no extra-articular manifestations), AS patients (BASDAI<4, CRP normal). We then analysed how many patients were successfully tapered at one year. Tapering schedule was decided by the supervising rheumatologist. Results  From December 2018 to February 2019, 66 patients were identified as being suitable for biologic tapering. 3 patients did not attend and were excluded from further analysis. Tapered group: 20 (32%) patients were tapered. Based on the retrospective review of clinic letters, the “tapering schedule” was inconsistent and the information provided to patients if they flared was also inconsistent - 9 (45%) patients were advised to return to their normal dose and only 1 (5%) patient was advised to contact the helpline. After 12 months of follow up, 11 (55%) patients remained on the tapered dose, 7 (35%) patients returned to their prior dose and 2 (10%) patients were lost to follow up. Non-tapered group: 43 (68%) patients were not tapered. The reasons for not tapering were divided into 6 broad categories: active disease (n = 15, 35%), patient choice (n = 5, 12%), DMARD was tapered instead (n = 5, 12%), discuss at next visit (n = 3, 7%), reason not mentioned (n = 12, 28%), other (n = 3, 7%) Conclusion  This Quality Improvement Project has highlighted the inconsistencies in biologic tapering in a UK real-world setting. In response to this inconsistency, we have developed a departmental guideline which provides stringent criteria to identify patients at lowest risk of flaring and standardises a tapering schedule and clinical pathway. We also created a patient information leaflet that could be distributed. Only half of the patients remained on the tapered dose after 1 year, suggesting a significant proportion of patients flare following dose reduction. However, our findings may be limited by small sample size. National guidance and a thorough audit based on this guidance is welcomed. Disclosure  Z. Rutter-locher: None. Y. Long Man: None. L. Marsh: None. S. Mercer: None. B. Menon: None. A. Cope: None.
Author Man, Yik Long
Menon, Bina
Rutter-locher, Zoe
Mercer, Scott
Cope, Andrew
Marsh, Lydia
Author_xml – sequence: 1
  givenname: Zoe
  surname: Rutter-locher
  fullname: Rutter-locher, Zoe
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
– sequence: 2
  givenname: Yik Long
  surname: Man
  fullname: Man, Yik Long
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
– sequence: 3
  givenname: Lydia
  surname: Marsh
  fullname: Marsh, Lydia
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
– sequence: 4
  givenname: Scott
  surname: Mercer
  fullname: Mercer, Scott
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
– sequence: 5
  givenname: Bina
  surname: Menon
  fullname: Menon, Bina
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
– sequence: 6
  givenname: Andrew
  surname: Cope
  fullname: Cope, Andrew
  organization: Guys and St Thomas' NHS trust, Rheumatology, London, UNITED KINGDOM
BookMark eNqNj81KAzEUhYNUsK2-w7zAtDe5SWa6lOIfFBTpPmSSmzo6nQyZFu1O8E19EltaxKWrczjwHfhGbNDGlhjLOEw4zHCaXmi7tpvYxNVu-ka2ErKYAPAzNuRSixwQxeC3C3nBRn3_CgCKYzlk4glAfH9-PZNt8veYGp_RR0epptZRn8WQVfXhu3bZxh72dnXJzoNtero65Zgtb2-W8_t88Xj3ML9e5G6GPPcFOFQkQilckEJqy3mF3hMqH2yoNCiHgDp4pb3mtrDcQaGxUlRq0hLHrDzeuhT7PlEwXarXNu0MB3NQN3_VzUnd7NX3KB7RuO3-T_0ARQ9mbA
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021
DBID AAYXX
CITATION
DOI 10.1093/rheumatology/keab247.001
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate British Society for Rheumatology Annual Conference 2021 Abstracts
EISSN 1462-0332
ExternalDocumentID 10_1093_rheumatology_keab247_001
10.1093/rheumatology/keab247.001
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AASNB
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADJQC
ADOCK
ADQBN
ADRIX
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFXEN
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHXPO
AIAGR
AIJHB
AJEEA
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
KAQDR
KBUDW
KC5
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RHF
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AAYXX
ABEJV
AHMMS
CITATION
ID FETCH-LOGICAL-c931-d70c35e2f82cf4246a11b3dde35dfafb605c3036fd56d61a7a1c0763b5e86e643
ISSN 1462-0324
IngestDate Fri Dec 06 01:01:41 EST 2024
Wed Aug 28 03:16:59 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c931-d70c35e2f82cf4246a11b3dde35dfafb605c3036fd56d61a7a1c0763b5e86e643
ParticipantIDs crossref_primary_10_1093_rheumatology_keab247_001
oup_primary_10_1093_rheumatology_keab247_001
PublicationCentury 2000
PublicationDate 2021-04-25
PublicationDateYYYYMMDD 2021-04-25
PublicationDate_xml – month: 04
  year: 2021
  text: 2021-04-25
  day: 25
PublicationDecade 2020
PublicationTitle Rheumatology (Oxford, England)
PublicationYear 2021
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0005138
Score 2.390192
Snippet Abstract Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on...
Background/Aims  Biologic therapy and treat to target have significantly improved patient outcomes and we now have a proportion of patients on biologic therapy...
SourceID crossref
oup
SourceType Aggregation Database
Publisher
Title P002 Real-world experiences of biologic tapering
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYWKiEuqC0gHm2VAzcwxHZee6woLaWA0GqRFi6REztiBdog2EXQExL_lF_CjO3smgoJysVKrGgSZ0aesf3NN4SsxaFqV-BJaaajEBYoitFCsYIqlQrJU6QYMwDZw2T3ONrrxb1W68ZDLY2GxWb598W8kvdoFfpAr5gl-x-aHQuFDrgG_UILGob2TTo-QmJTi1bIRAdCPmoIUB1tv0FIYzBoiZb65fpQXhrmQT8i7ZzpEUStlooJuUdvG7i7q-_h7RV0TFVrelE3mj6tPeismb9O-ufr-7V7haUpuDY7N_t3qj92AQcIp7EVv5Abwt964AxPUWyaspsto4TTUNgk6E3t94lnU6wtGeBMyZQrNXufOXtxErcEV1fe8OH2XMuCR8g3ySauqzmu_8ejjXGG9oRd5L6s3ElCNN8U-YAEilhz4cfvPxNoEDMV0MfDcwgwkLTlS9ryvulZWIOpkl6U0v1I5tzyIvhubeUTaenBZzJz4AAU84SjyTzeP0yMJfCMJairoDGWoDGWBdL9udPd3qWubAYt24JRlYaliDWvMl5WEY8SyVghwIuJWFWyKmD9WmLcUqk4UQmTqWRlCF6miHWWaAhQF8n0oB7oJRJwxROFJcp4ig5VZZqXsh0LWLZKkJsuE9YMOr-05Cj5a798mWzA33nz4yvveMUqmZ1Y6xcyPbwa6a8QOg6Lb0bP0P7qsSe2vHHb
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P002%E2%80%83Real-world+experiences+of+biologic+tapering&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Rutter-locher%2C+Zoe&rft.au=Man%2C+Yik+Long&rft.au=Marsh%2C+Lydia&rft.au=Mercer%2C+Scott&rft.date=2021-04-25&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=60&rft.issue=Supplement_1&rft_id=info:doi/10.1093%2Frheumatology%2Fkeab247.001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keab247_001
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon